Stock listing
Munich:V7B Assembly Biosciences, Inc. Aktie
German listing (Munich) of Assembly Biosciences, Inc. · home listing NASDAQ:ASMB
Follow Assembly Biosciences, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:ASMB
$22.19 USD -0.20 (-0.9%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ASMB
- Day range
- $21.87 – $22.79 USDNov 20, 2026
- Volume
- 480,921 sharesNov 20, 2026
- Market cap
- $454.4M USDAt the close on Nov 20, 2026 · price × 20.48M shares outstanding
- 52-week range
- $19.20 – $39.65 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $7.86M USDMedian day 249,358 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ASMB · Home | $22.19 USD | -0.20 (-0.9%) | 480,921 | $22.24 | $22.79 | $21.87 | $22.39 | Close on Nov 20, 2026 |
| Frankfurt:V7B | €19.98 EUR | -0.42 (-2.1%) | — | €19.98 | €19.98 | €19.98 | €20.40 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ASMB · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $22.19 | -0.20 | -0.9% | $22.24 | $22.79 | $21.87 | 480,921 | |
| $22.39 | -0.11 | -0.5% | $22.50 | $23.50 | $22.07 | 486,346 | |
| $22.50 | +1.21 | +5.7% | $21.28 | $22.60 | $21.15 | 326,387 | |
| $21.29 | +0.17 | +0.8% | $21.12 | $21.81 | $21.00 | 514,286 | |
| $21.12 | +0.94 | +4.7% | $19.96 | $21.21 | $19.22 | 318,868 | |
| $20.18 | -2.19 | -9.8% | $22.10 | $22.10 | $19.84 | 499,583 | |
| $22.37 | +1.02 | +4.8% | $21.11 | $22.69 | $21.00 | 203,140 | |
| $21.35 | -0.44 | -2.0% | $21.30 | $21.69 | $20.77 | 263,292 | |
| $21.79 | +1.37 | +6.7% | $20.60 | $21.82 | $20.03 | 313,333 | |
| $20.42 | +0.42 | +2.1% | $20.00 | $21.10 | $20.00 | 249,358 | |
| $20.00 | +0.13 | +0.7% | $20.00 | $20.06 | $19.20 | 518,399 | |
| $19.87 | -0.05 | -0.3% | $20.32 | $20.54 | $19.64 | 269,004 | |
| $19.92 | +0.41 | +2.1% | $19.71 | $20.32 | $19.50 | 170,886 | |
| $19.51 | -0.62 | -3.1% | $20.37 | $20.77 | $19.25 | 262,713 | |
| $20.13 | -0.73 | -3.5% | $20.86 | $21.00 | $19.98 | 136,867 | |
| $20.86 | +0.29 | +1.4% | $20.75 | $21.36 | $20.71 | 198,747 | |
| $20.57 | +0.27 | +1.3% | $20.21 | $20.66 | $19.95 | 142,684 | |
| $20.30 | +0.63 | +3.2% | $19.56 | $20.60 | $19.56 | 185,733 | |
| $19.67 | -0.17 | -0.9% | $19.97 | $20.09 | $19.59 | 152,175 | |
| $19.84 | -0.44 | -2.2% | $20.34 | $20.34 | $19.30 | 206,013 | |
| $20.28 | -0.18 | -0.9% | $20.29 | $20.85 | $19.98 | 137,800 | |
| $20.46 | -0.73 | -3.4% | $21.42 | $21.93 | $20.38 | 234,800 | |
| $21.19 | +1.03 | +5.1% | $20.23 | $21.48 | $20.07 | 222,800 | |
| $20.16 | +0.07 | +0.3% | $20.22 | $20.49 | $19.95 | 199,200 | |
| $20.09 | -0.48 | -2.3% | $20.63 | $20.63 | $19.94 | 167,700 | |
| $20.57 | +0.04 | +0.2% | $20.73 | $21.04 | $20.41 | 204,200 | |
| $20.53 | +0.19 | +0.9% | $20.19 | $20.99 | $19.98 | 241,300 | |
| $20.34 | -2.43 | -10.7% | $22.64 | $22.64 | $20.28 | 305,600 | |
| $22.77 | -0.76 | -3.2% | $23.43 | $23.83 | $22.44 | 207,800 | |
| $23.53 | +0.71 | +3.1% | $23.00 | $23.58 | $22.72 | 170,500 | |
| $22.82 | -0.13 | -0.6% | $22.78 | $23.05 | $22.08 | 288,400 | |
| $22.95 | +0.77 | +3.5% | $21.95 | $23.13 | $21.80 | 190,800 | |
| $22.18 | -0.56 | -2.5% | $22.84 | $22.92 | $21.80 | 349,200 | |
| $22.74 | +0.20 | +0.9% | $22.68 | $22.95 | $22.27 | 241,700 | |
| $22.54 | -0.44 | -1.9% | $23.30 | $23.48 | $22.01 | 368,000 | |
| $22.98 | -0.51 | -2.2% | $23.18 | $23.66 | $22.75 | 350,800 | |
| $23.49 | +0.01 | 0.0% | $23.65 | $23.87 | $23.23 | 221,100 | |
| $23.48 | -0.13 | -0.6% | $23.70 | $23.79 | $23.05 | 229,700 | |
| $23.61 | -0.06 | -0.3% | $23.35 | $23.86 | $23.05 | 117,500 | |
| $23.67 | +0.01 | 0.0% | $23.70 | $24.25 | $23.43 | 143,500 | |
| $23.66 | -0.31 | -1.3% | $23.73 | $24.02 | $23.15 | 179,000 | |
| $23.97 | -1.48 | -5.8% | $25.42 | $25.63 | $23.89 | 275,200 | |
| $25.45 | +0.01 | 0.0% | $25.69 | $25.89 | $25.12 | 1,070,100 | |
| $25.44 | +0.47 | +1.9% | $25.40 | $25.73 | $24.85 | 211,900 | |
| $24.97 | -0.37 | -1.5% | $25.41 | $25.78 | $24.83 | 1,413,900 | |
| $25.34 | -0.14 | -0.5% | $26.02 | $26.30 | $25.10 | 364,800 | |
| $25.48 | -0.63 | -2.4% | $26.11 | $26.69 | $25.13 | 348,800 | |
| $26.11 | -2.85 | -9.8% | $29.00 | $29.66 | $25.31 | 588,800 | |
| $28.96 | -0.84 | -2.8% | $30.31 | $30.48 | $28.79 | 290,100 | |
| $29.80 | -0.66 | -2.2% | $30.83 | $31.72 | $29.68 | 258,900 | |
| $30.46 | -2.41 | -7.3% | $32.56 | $32.69 | $30.34 | 348,600 | |
| $32.87 | -2.41 | -6.8% | $35.64 | $35.93 | $32.73 | 724,800 | |
| $35.28 | -1.32 | -3.6% | $36.16 | $36.68 | $35.15 | 227,700 | |
| $36.60 | +0.47 | +1.3% | $35.68 | $36.77 | $35.49 | 156,500 | |
| $36.13 | -0.59 | -1.6% | $36.80 | $36.80 | $35.54 | 225,000 | |
| $36.72 | +1.54 | +4.4% | $35.48 | $37.01 | $34.86 | 267,500 | |
| $35.18 | +1.55 | +4.6% | $34.12 | $35.33 | $33.43 | 301,100 | |
| $33.63 | -0.44 | -1.3% | $33.80 | $34.30 | $32.92 | 236,000 | |
| $34.07 | -0.73 | -2.1% | $34.58 | $34.58 | $33.29 | 250,000 | |
| $34.80 | -0.62 | -1.8% | $35.32 | $35.90 | $34.75 | 192,100 | |
| $35.42 | +0.09 | +0.3% | $35.38 | $36.13 | $35.00 | 171,500 | |
| $35.33 | +0.05 | +0.1% | $36.00 | $37.00 | $35.19 | 553,800 | |
| $35.28 | +0.90 | +2.6% | $34.38 | $36.12 | $33.75 | 383,900 | |
| $34.38 | +0.85 | +2.5% | $33.86 | $35.62 | $33.86 | 341,500 | |
| $33.53 | -0.31 | -0.9% | $33.54 | $34.00 | $32.90 | 215,000 |
Splits
2 splits since 2014 · NASDAQ:ASMB · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-12 | Consolidation | |
| 1-for-5 | Consolidation |
- Ticker
- Munich:V7B
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Munich
- Currency
- EUR
What changed lately
Latest news release · Nov 12, 2026
Assembly Biosciences Reports Third Quarter 2026 Financial Results and Recent Updates
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 37 slides
Latest news
Assembly Biosciences Reports Third Quarter 2026 Financial Results and Recent Updates
Nov 12, 2026
Closed $21.12 (+4.7%) on Nov 13, 2026
Assembly Biosciences to Participate in Upcoming Investor Conferences
Nov 2, 2026
Closed $19.92 (+2.1%) on Nov 3, 2026
Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus
Oct 29, 2026
Closed $20.13 (-3.5%) on Oct 30, 2026
Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026
Oct 5, 2026
Closed $22.74 (+0.9%) on Oct 5, 2026
Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference
Sep 10, 2026
Closed $29.80 (-2.2%) on Sep 11, 2026
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program
Sep 8, 2026
Closed $32.87 (-6.8%) on Sep 9, 2026
Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
Aug 13, 2026
Closed $32.95 (+10.0%) on Aug 14, 2026
Assembly Biosciences Announces Upcoming Investor Conference Presentations
May 28, 2026
Closed $27.66 (-0.3%) on May 29, 2026
Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
May 26, 2026
Closed $27.40 (-4.7%) on May 27, 2026
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
May 22, 2026
Closed $28.34 (+6.9%) on May 22, 2026
Assembly Biosciences, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 19 in the last 12 months · 134 in all · newest Nov 12, 2026 · oldest 2019
- Calls
- 1 call with a replay · 1 with a transcript · latest Nov 5, 2020
- Decks
- 16 decks · latest September 2026
Where Assembly Biosciences, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ASMB · Home listing | NASDAQ | United States | USD |
| Tradegate:V7B | Tradegate | Germany | EUR |
| LS Exchange:A402CB | LS Exchange | Germany | EUR |
| gettex:V7B | gettex | Germany | EUR |
| Lang & Schwarz:A402CB | Lang & Schwarz | Germany | EUR |
| BOATS:ASMB | BOATS | United States | USD |
| Frankfurt:V7B | Frankfurt | Germany | EUR |
| Dusseldorf:V7B | Dusseldorf | Germany | EUR |
| Hamburg:V7B | Hamburg | Germany | EUR |
| Munich:V7B · This page | Munich | Germany | EUR |
| Stuttgart:V7B | Stuttgart | Germany | EUR |
Valuation
EV/sales 2.1× against a median of 21.2×: the lowest of 5 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $142.3M USD
- P/E
- Loss
- EV/sales
- 2.1×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.5×
- Gross margin
- 99.9%
- Operating margin
- −31.8%
- Net margin
- −16.6%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.00
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Assembly Biosciences, Inc. · NASDAQ:ASMB | US$454.4M | US$142.3M | n/a | 2.1× | n/a | 1.5× | −16.6% | 0.0× | 1.00 |
| Monopar Therapeutics Inc. · NASDAQ:MNPR | US$467.6M | US$362.8M | n/a | n/a | n/a | 3.7× | n/a | 0.0× | 1.18 |
| BlossomHill Therapeutics, Inc. · NASDAQ:BLSM | US$461.2M | US$259.4M | n/a | n/a | n/a | 2.2× | n/a | 0.1× | n/a |
| Neurogene Inc. · NASDAQ:NGNE | US$458.5M | US$106.4M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | 1.47 |
| Shattuck Labs, Inc. · NASDAQ:STTK | US$454.2M | US$260.4M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.10 |
| G2GBIO, Inc. · KRX:456160 | US$449.3M | US$289.1M | n/a | 176× | n/a | 4.3× | −793.7% | 0.0× | n/a |
| DiaMedica Therapeutics Inc. · NASDAQ:DMAC | US$445.1M | US$410.4M | n/a | n/a | n/a | 15.5× | n/a | 0.0× | 1.67 |
| CytomX Therapeutics, Inc. · NASDAQ:CTMX | US$442.5M | US$98.96M | n/a | 7.0× | n/a | 1.6× | −609.0% | 0.0× | 1.21 |
| Hansa Biopharma AB · OMXSTO:HNSA | US$441.3M | US$488.5M | n/a | 26.3× | n/a | n/a | −406.5% | n/a | n/a |
| Capricor Therapeutics, Inc. · NASDAQ:CAPR | US$441.3M | US$335.9M | n/a | n/a | n/a | 2.1× | n/a | 0.4× | 0.94 |
| Shanghai MicuRx Pharmaceutical Co., Ltd. Class A · SSE:688373 | US$439.3M | US$408.1M | n/a | 16.2× | n/a | 19.4× | −57.0% | 0.9× | n/a |
| Median of the others | US$447.2M | US$312.5M | 21.2× | 2.4× | −507.7% | 0.0× | 1.19 |
Forecasts
5 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 51.20 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.12 · 4 analysts
- Revenue, year to Dec 2026
- 63.43M · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Jason Okazaki | Chief Executive Officer & President, Director |
| Shannon Ryan | SVP, Investor Relations, Corporate Affairs and Alliance Management |
Board
| Director | Role |
|---|---|
| Anthony Altig | Chairman of the Board, Non-Executive |
| Gina Consylman | Director |
| Jason Okazaki | Chief Executive Officer & President, Director |
| John McHutchison | Director |
| Lisa Johnson-Pratt | Director |
| Michael Houghton | Director |
| Rob Cook | Director |
| Sue Mahony | Director |
| Tomas Cihlar | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Assembly Biosciences (NASDAQ:ASMB) Q3 2020 Earnings Call | Thu, Nov 05, 2020 · 5:00 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | +4.7% |
| Q2 2026 | Aug 13, 2026 · After close | +10.0% |
| Q1 2026 | May 7, 2026 · After close | −3.9% |
| Q3 2025 | Nov 10, 2025 · After close | +3.3% |
| Q2 2025 | Aug 6, 2025 · After close | +9.2% |
| Q1 2025 | May 8, 2025 · After close | +5.0% |
| Q4 2024 | Mar 26, 2025 · Before open | −5.3% |
| Q3 2024 | Nov 7, 2024 · After close | −4.1% |
| Q2 2024 | Aug 8, 2024 · After close | −2.8% |
| Q1 2024 | May 8, 2024 · After close | +1.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Jan 31, 2024 · After close | +0.7% |
| Q3 2023 | Nov 8, 2023 · After close | −12.5% |
| Q2 2023 | Aug 9, 2023 · After close | +0.9% |
| Q1 2023 | May 4, 2023 · After close | −1.0% |
| Q4 2022 | Mar 22, 2023 · After close | −8.6% |
| Q3 2022 | Nov 8, 2022 · After close | −4.4% |
| Q2 2022 | Aug 9, 2022 · After close | +0.5% |
| Q1 2022 | May 12, 2022 · After close | +6.2% |
| Q4 2021 | Mar 10, 2022 · After close | −1.3% |
| Quarter to Sep 30, 2021 | Nov 4, 2021 · After close | −1.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 37 slides | September 2026 |
| Technical Presentation (October 2025) | Technical | 15 slides | October 2025 |
| Technical Presentation (August 2022) | Technical | 43 slides | Aug 31, 2022 |
| Technical Presentation (July 2022) | Technical | 55 slides | Jul 26, 2022 |
| AASLD 2019 Review | Conference | 21 slides | Nov 12, 2019 |
| Investor Day (June 2018) | Investor day | 66 slides | Jun 20, 2018 |
| Investor Presentation (September 2017) | Investor deck | 37 slides | Sep 26, 2017 |
| Technical Presentation (September 2017) | Technical | 31 slides | Sep 25, 2017 |
| Investor Presentation (September 2017) | Investor deck | 29 slides | Sep 7, 2017 |
| Investor Presentation (January 2017) | Investor deck | 25 slides | Jan 9, 2017 |
All 16 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2016) | Investor deck | 23 slides | Nov 9, 2016 |
| RBC Capital Markets 2016 Healthcare Conference | Conference | 22 slides | Feb 24, 2016 |
| Investor Presentation (January 2016) | Investor deck | 22 slides | Jan 12, 2016 |
| Investor Presentation (January 2016) | Investor deck | 22 slides | January 2016 |
| Investor Presentation (February 2015) | Investor deck | 54 slides | Feb 24, 2015 |
| Investor Presentation (August 2014) | Investor deck | 21 slides | Aug 13, 2014 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants with accompanying Class A and Class B warrants Announced: US$19.6 a share · Warrants at US$21.6 for 60 months · Guggenheim Securities +1 Dealers: Guggenheim Securities (lead), Mizuho (co-lead) Buyers: Commodore Capital; Blackstone Multi-Asset Investing; Farallon Capital Management, L.L.C.; Janus Henderson Investors; RA Capital Management Use of proceeds: General corporate purposes | Aug 8, 2025 |
| Private placement of common stock with accompanying Class A and Class B warrants Announced: private placement Buyers: Gilead Sciences, Inc. (2,295,920 shares of common stock and accompanying Class A and Class B warrants to purchase up to 2,295,920 shares) Use of proceeds: General corporate purposes | Aug 8, 2025 |
| Strategic investment of common stock Closed: US$20.1M raised Buyers: Gilead (approximately $20.1 million equity investment) Use of proceeds: To advance clinical development programs | Mar 20, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as VENTRUS BIOSCIENCES INC. Priced at US$6.00 a share on Dec 16, 2010.
- Price
- US$6.00 a share
- Shares offered
- 2,900,000 shares of common stock
- Offering size
- US$17.4 million
- Underwriters' option
- Up to 435,000 more shares
- Underwriters
- Rodman & Renshaw, LLC, National Securities Corporation · In the order on the cover
- Shares delivered
- On or about Dec 22, 2010
Steps
| Step | When |
|---|---|
| Filed publicly | Jul 20, 2010 |
| Amended 5 times | Newest Dec 9, 2010 |
| Shares registered with an exchange | Dec 10, 2010 |
| Declared effective by the SEC | Dec 15, 2010 |
| Final prospectus, with the price | Dec 17, 2010 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Dec 17, 2010 |
| S-1MEF · Registration of more shares for the same offering | Dec 16, 2010 |
| CERTNAS · Nasdaq's certificate of listing | Dec 15, 2010 |
| EFFECT · Notice that a registration is effective | Dec 15, 2010 |
| CORRESP · Letter to the SEC | Dec 14, 2010 |
| 8-A12B · Registration of shares for listing on an exchange | Dec 10, 2010 |
| S-1/A · Registration statement, amended | Dec 9, 2010 |
| UPLOAD · Letter from the SEC | Dec 8, 2010 |
| S-1/A · Registration statement, amended | Dec 6, 2010 |
| UPLOAD · Letter from the SEC | Nov 22, 2010 |
All 18 filings
| Filing | Filed |
|---|---|
| 8-A12G · Registration of a class of shares | Nov 16, 2010 |
| S-1/A · Registration statement, amended | Nov 16, 2010 |
| UPLOAD · Letter from the SEC | Nov 8, 2010 |
| S-1/A · Registration statement, amended | Oct 29, 2010 |
| UPLOAD · Letter from the SEC | Oct 19, 2010 |
| S-1/A · Registration statement, amended | Oct 4, 2010 |
| UPLOAD · Letter from the SEC | Aug 16, 2010 |
| S-1 · Registration statement | Jul 20, 2010 |
Open IPO · From the cover of the final prospectus (424B4) filed Dec 17, 2010
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 72.3M | 28.5M | 7.16M | 0 | 6.25M | 79.1M | 16.0M | 14.8M | 9.02M | 0 |
| Cost of revenue | 129.0K | 55.9M | 48.9M | 498.0K | 466.0K | 101.3M | 85.8M | 72.7M | 44.2M | 80.3K |
| Gross profit | 72.2M | -27.4M | -41.7M | -498.0K | 6.25M | -22.2M | 16.0M | -57.9M | -35.2M | -80.3K |
| Research and development | 64.8M | 55.9M | 48.9M | 70.0M | 68.5M | 106.8M | 85.8M | 72.7M | 44.2M | 33.1M |
| Selling, general and administrative | 19.6M | 18.0M | 22.9M | 24.1M | 28.8M | 36.9M | 32.9M | 34.8M | 17.0M | 12.2M |
| Operating income | -12.1M | -45.4M | -64.6M | -94.1M | -132.7M | -64.8M | -102.7M | -92.7M | -52.2M | -45.3M |
| Depreciation and amortization | 129.0K | 129.0K | 450.0K | 498.0K | 466.0K | 691.0K | 494.0K | 643.0K | 219.0K | 80.0K |
| EBITDA | -12.0M | -45.3M | -64.2M | -93.6M | -132.2M | -64.1M | -102.2M | -92.1M | -52.0M | -45.2M |
| Interest expense | 498.0K | 82.5M | 2.62M | 4.80M | 0 | 0 | 0 | |||
| Income before tax | -6.12M | -39.8M | -61.2M | -93.1M | -132.4M | -62.2M | -98.4M | -89.7M | -51.9M | -44.9M |
| Income tax | 0 | 330.0K | 33.0K | 0 | -2.53M | 0 | -774.0K | 1.10M | -9.05M | -618.0K |
| Net income | -6.12M | -40.2M | -61.2M | -93.1M | -129.9M | -62.2M | -97.6M | -90.8M | -42.8M | -44.3M |
| Earnings per share, basic | -0.55 | -6.69 | -13.38 | -23.08 | -3.00 | -1.75 | -3.72 | -3.98 | -2.41 | -2.57 |
| Earnings per share, diluted | -0.55 | -6.69 | -13.38 | -23.08 | -3.00 | -1.75 | -3.72 | -3.98 | -2.41 | -2.57 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 58.5M | 38.3M | 19.8M | 52.4M | 45.6M | 59.4M | 46.7M | 41.5M | 82.0M | 28.6M |
| Short-term investments | 189.7M | 73.7M | 110.4M | 39.2M | 101.0M | 157.0M | 227.3M | 176.6M | 37.9M | 24.4M |
| Receivables | 974.0K | 0 | 43.0K | 944.0K | 336.0K | 1.23M | 3.37M | 2.43M | 2.27M | 0 |
| Inventory | -3.20M | 1 | 1 | 0 | 0 | 1 | 1 | 0 | ||
| Current assets | 254.5M | 115.5M | 133.8M | 97.0M | 154.2M | 224.5M | 282.8M | 222.5M | 123.1M | 53.6M |
| Property, plant and equipment | 221.0K | 284.0K | 385.0K | 743.0K | 1.14M | 1.60M | 1.83M | 557.0K | 860.0K | 214.7K |
| Goodwill | 0 | 12.6M | 12.6M | 12.6M | 12.6M | 12.6M | ||||
| Total assets | 257.6M | 119.2M | 136.8M | 101.8M | 191.1M | 283.3M | 339.9M | 268.0M | 169.3M | 98.1M |
| Accounts payable | 1.17M | 585.0K | 461.0K | 2.49M | 2.66M | 4.60M | 1.73M | 3.69M | 2.12M | 2.37M |
| Current liabilities | 48.8M | 47.8M | 39.2M | 16.3M | 16.1M | 24.4M | 24.4M | 18.5M | 13.5M | 7.12M |
| Long-term debt | 0 | 0 | ||||||||
| Total debt | 2.63M | 3.09M | 2.34M | 3.46M | 6.48M | 10.1M | 12.3M | |||
| Total liabilities | 50.8M | 85.8M | 95.7M | 19.1M | 22.1M | 42.7M | 66.7M | 57.4M | 56.2M | 18.2M |
| Shareholders' equity | 206.8M | 33.4M | 41.1M | 82.7M | 168.9M | 240.6M | 273.2M | 210.7M | 113.1M | 79.9M |
| Shares outstanding | 15.9M | 7.46M | 5.48M | 4.07M | 48.1M | 34.0M | 32.6M | 25.5M | 20.1M | 17.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -41.1M | -51.1M | 22.7M | -84.5M | -93.4M | -63.0M | -84.1M | -65.0M | 1.86M | -34.9M |
| Capital spending | -66.0K | -28.0K | -255.0K | -102.0K | -3.10M | -470.0K | -1.55M | -340.0K | -865.0K | -147.0K |
| Free cash flow | -41.2M | -51.1M | 22.5M | -84.6M | -96.5M | -63.4M | -85.6M | -65.3M | 995.0K | -35.0M |
| Cash from investing | -113.5M | 40.2M | -69.1M | 90.6M | 26.5M | 68.1M | -50.3M | -135.4M | -15.6M | 36.2M |
| Cash from financing | 174.7M | 29.4M | 13.8M | 614.0K | 53.1M | 7.60M | 139.6M | 159.8M | 67.2M | 153.0K |
| Dividends paid | 0 | 0 | ||||||||
| Share buybacks | 614.0K | 7.60M | 139.6M | 159.8M | 67.2M | 152.6K | ||||
| Change in cash | 20.1M | 18.5M | -32.6M | 6.79M | -13.8M | 12.7M | 5.26M | -40.6M | 53.5M | 1.47M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 2, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 144 · Notice of proposed sale | Nov 2, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Aug 20, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 8-K/A · Current report, amended | Aug 14, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2026 | Acquisition or disposal | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 4, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 5, 2026 | Management or board change | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 26, 2026 | Material contract | SEC |
| 424B5 · Prospectus | May 22, 2026 | Offer document | SEC |
| 424B5 · Prospectus | May 22, 2026 | Offer document | SEC |
| 8-K · Current report | May 22, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | May 11, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 22, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 22, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 22, 2026 | Annual report | SEC |
| 4 · Change in ownership | Mar 31, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 31, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 31, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 31, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 31, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 30, 2026 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Mar 30, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 25, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 24, 2026 | Other filings | SEC |
| S-3 · Registration statement | Mar 19, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 19, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 19, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 19, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 9, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Dec 8, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 8, 2025 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Nov 24, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Nov 21, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Nov 19, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 10, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2025 | Results | SEC |
| S-3 · Registration statement | Oct 14, 2025 | Offer document | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 18, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 18, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 12, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 11, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Aug 11, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Aug 11, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 8, 2025 | Current report | SEC |
| S-3MEF | Aug 7, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Aug 6, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2025 | Results | SEC |
| 8-K · Current report | Jun 25, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 9, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 23, 2025 | Annual report | SEC |
| 4 · Change in ownership | Apr 15, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Apr 2, 2025 | Other filings | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Mar 28, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 26, 2025 | Other filings | SEC |
| S-3 · Registration statement | Mar 20, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 20, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 20, 2025 | Results | SEC |
| 8-K · Current report | Feb 20, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 3, 2025 | Material contract | SEC |
| 4 · Change in ownership | Dec 31, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 26, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 23, 2024 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 23, 2024 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 23, 2024 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 23, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Dec 19, 2024 | Material contract | SEC |
| 8-K · Current report | Dec 13, 2024 | Current report | SEC |
| 4 · Change in ownership | Nov 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 7, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Nov 7, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| 4 · Change in ownership | Oct 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 4, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 23, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | Aug 8, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 4 · Change in ownership | Aug 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Jun 24, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Jun 20, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 18, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Jun 18, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 3, 2024 | Management or board change | SEC |
| 4 · Change in ownership | May 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2024 | Results | SEC |
| 4 · Change in ownership | May 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2024 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Apr 17, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 17, 2024 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 17, 2024 | Annual report | SEC |
| 4 · Change in ownership | Apr 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 29, 2024 | Insider trade | SEC |
| 10-K · Annual report | Mar 28, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 28, 2024 | Results | SEC |
| 3 · Initial statement of ownership | Mar 15, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 15, 2024 | Management or board change | SEC |
| 8-K · Current report | Feb 13, 2024 | Current report | SEC |
| 8-K · Current report | Feb 2, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Jan 19, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 17, 2024 | Current report | SEC |
| DEFA14A · Additional proxy material | Dec 21, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Dec 21, 2023 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Dec 11, 2023 | Meeting notice | SEC |
| 3 · Initial statement of ownership | Dec 11, 2023 | Insider trade | SEC |
| 8-K · Current report | Dec 7, 2023 | Management or board change | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 22, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 13, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 8, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 8, 2023 | Results | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 3, 2023 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Oct 31, 2023 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Oct 31, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 25, 2023 | Insider trade | SEC |
| SC 13D · Big-stake notice | Oct 25, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Oct 17, 2023 | Material contract | SEC |
| 4 · Change in ownership | Oct 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 4, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 3, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 3, 2023 | Other filings | SEC |
| 8-K · Current report | Sep 29, 2023 | Current report | SEC |
| 3 · Initial statement of ownership | Sep 18, 2023 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Aug 9, 2023 | Offer document | SEC |
This page holds 200 of 904 filings. Open Filings
Cap table
Built by 6ix from Assembly Biosciences, Inc.’s releases · as of Nov 6, 2026
- Common shares
- 20,477,244
- Fully diluted
- 20,477,244
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 20,477,244 | Nov 6, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 6, 2026 | 20,477,244 |
| Sep 30, 2026 | 20,368,351 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| William R Ringo Other companies: Sensei Biotherapeutics, Inc. (Director · Mar 8, 2022 – May 21, 2025 · Past); Five Prime Therapeutics Inc (Director · Oct 1, 2014 – Apr 5, 2021 · Past); Immune Design Corp (Director · Jul 23, 2014 – Apr 2, 2019 · Past); Onyx Pharmaceuticals Inc (Director · Feb 3, 2011 – Oct 1, 2013 · Past); Sangamo Therapeutics, Inc. (Director · Apr 16, 2010 – Sep 20, 2017 · Past); Pfizer, Inc. (Senior Vice President · Apr 1, 2008 – Mar 31, 2010 · Past); Allos Therapeutics Inc (Director · Jan 5, 2007 – Jun 19, 2007 · Past); Inspire Pharmaceuticals Inc (Director · Jun 13, 2006 – Jun 8, 2007 · Past); Abgenix Inc (CEO and President, Director · Apr 1, 2006 – Apr 1, 2006 · Past); InterMune Inc (Director · Feb 23, 2006 – May 15, 2007 · Past) | Director · Since at least Jul 10, 2014 |
| Graham Cooper Other companies: Beam Therapeutics Inc. (Director · Since at least Feb 5, 2020); Kezar Life Sciences, Inc. (Director · Since at least Jun 20, 2018); Nuvation Bio Inc. (Director · Jun 30, 2020 – Feb 10, 2021 · Past); Applied Molecular Transport Inc (Director · Jun 4, 2020 – Jan 27, 2022 · Past); Unity Biotechnology Inc (Director · May 2, 2018 – Jun 24, 2021 · Past); Eiger Biopharmaceuticals Inc (Director · Jan 29, 2014 – Jun 4, 2015 · Past); Receptos Inc (Chief Financial Officer · May 8, 2013 – Aug 27, 2015 · Past); Geron Corporation (EVP, Bus Dev & CFO · Jan 5, 2012 – May 17, 2012 · Past); Orexigen Therapeutics Inc (CFO and Treasurer · Apr 25, 2007 – Jan 18, 2011 · Past) | See Remarks · Mar 8, 2018 – Mar 29, 2019 · Past |
| Helen Susan Kim Other companies: Aktis Oncology, Inc. (Director · Since at least Jan 8, 2026); Prothena Corporation plc (Director · Aug 30, 2022 – May 14, 2025 · Past); Applied Molecular Transport Inc (Director · Jun 4, 2020 – Aug 26, 2021 · Past); Exicure, Inc. (Director · Sep 26, 2017 – Jun 4, 2020 · Past); Kite Pharma Inc (EVP, Business Development · Apr 14, 2015 – Oct 3, 2017 · Past); Sunesis Pharmaceuticals Inc (Director · Jul 24, 2009 – Jun 30, 2015 · Past); Kosan Biosciences Inc (President and CEO · Jan 3, 2008 – Jun 26, 2008 · Past) | Director · Mar 8, 2018 – Jun 11, 2020 · Past |
| Gina Consylman Other companies: Bluebird bio Inc (Chief Financial Officer · Nov 4, 2021 – Feb 1, 2022 · Past); Cyclerion Therapeutics, Inc. (SECRETARY AND TREASURER, Director · Mar 14, 2019 – Mar 14, 2019 · Past); Verastem, Inc. (Director · Oct 17, 2018 – Jun 28, 2021 · Past); Ironwood Pharmaceuticals, Inc. (SVP, CFO & Treasurer · Jun 23, 2014 – Mar 26, 2021 · Past); Analogic Corporation (VP-Controller · Mar 1, 2013 – Jun 11, 2014 · Past) | Director · Since at least Oct 19, 2020 |
| Susan Mahony Other companies: Axsome Therapeutics, Inc. (DIRECTOR · Since at least Oct 10, 2023); Zymeworks Inc. (Director · Since at least Jun 3, 2019); Eli Lilly and Company (SVP & Pres., Lilly Oncology · Jul 28, 2015 – Apr 13, 2018 · Past) | Director · Since at least Dec 14, 2017 |
| Anthony Altig Other companies: Optimer Pharmaceuticals Inc (Director · Jan 1, 2012 – Oct 24, 2013 · Past); TearLab Corporation (TEAR) (Director · Oct 1, 2011 – Jul 9, 2020 · Past) | Chairman of the Board, Non-Executive · Since at least Jan 17, 2012 |
| John McHutchison Other companies: Metacrine Inc (Director · Sep 15, 2020 – May 18, 2022 · Past); Gilead Sciences, Inc. (Chief Scientific Off/HeadR&D · Apr 23, 2018 – Feb 6, 2019 · Past) | Director · Since at least Aug 6, 2019 |
| Lee D Arnold Other companies: Aethlon Medical, Inc. (Chief Scientific Officer · Feb 1, 2023 – Feb 1, 2023 · Past); Pardes Biosciences Inc (Chief Scientific Officer · Dec 23, 2021 – Feb 1, 2022 · Past) | Chief Scientific Officer · Jul 11, 2014 – Jul 11, 2014 · Past |
| Myron Holubiak Other companies: Citius Oncology, Inc. (Secretary · Since at least Aug 12, 2024); Citius Pharmaceuticals, Inc. (Co-Founder, Executive Vice Chairman · Since at least Mar 28, 2018) | Director · May 30, 2018 – May 20, 2021 · Past |
| Sue Mahony Other companies: Theravance Biopharma, Inc. (Lead Independent Director · Since at least Nov 4, 2026); Zymeworks Inc. (Lead Independent Director · Since at least Aug 11, 2025) | Director · Since at least Nov 4, 2026 |
All 37 people
| Person | Seat |
|---|---|
| Alan Lewis Other companies: BioMarin Pharmaceutical Inc. (Director · Jun 4, 2019 – Jun 4, 2019 · Past) | Director · May 17, 2019 – Jun 11, 2020 · Past |
| David Jonathan Barrett Other companies: Fortress Biotech, Inc. (Director · Dec 19, 2013 – Feb 20, 2014 · Past) | See Remarks · Apr 5, 2013 – Mar 29, 2017 · Past |
| Derek A Small Other companies: Innoviva, Inc. (Director · Since at least Apr 29, 2024) | Director · Jul 11, 2014 – Jan 2, 2020 · Past |
| Mark Auerbach Other companies: Pardes Biosciences Inc (Director · Dec 23, 2021 – Aug 31, 2023 · Past) | Director · May 30, 2018 – May 17, 2019 · Past |
| Michael P Samar Other companies: Unity Biotechnology Inc (Director · May 25, 2022 – Jun 21, 2024 · Past) | Chief Financial Officer · May 1, 2019 – Jul 25, 2022 · Past |
| Miguel Barbosa Other companies: Synlogic Inc (Chief Scientific Officer · Sep 30, 2015 – Sep 30, 2015 · Past) | See Remarks · Oct 6, 2016 – Oct 6, 2016 · Past |
| Richard D DiMarchi Other companies: Ionis Pharmaceuticals, Inc. (Director · Jul 3, 2006 – Jul 1, 2010 · Past) | Director · Jul 10, 2014 – May 25, 2022 · Past |
| Russell H Ellison Other companies: Rockwell Medical, Inc. (See Remarks, Director · Jan 9, 2020 – May 3, 2021 · Past) | Chief Executive Officer, Director · Apr 5, 2013 – Jul 10, 2014 · Past |
| Thomas Joseph Russo Other companies: Icosavax Inc (Chief Financial Officer · Jul 28, 2021 – Dec 20, 2023 · Past) | CFO · Oct 28, 2019 – Mar 29, 2021 · Past |
| Thomas Rowland Other companies: ANI Pharmaceuticals, Inc. (Senior Vice President, Head of Established Brands · Since at least Mar 28, 2024) | Chief Business Officer · Dec 15, 2010 – Jan 15, 2012 · Past |
| Uri A Lopatin Other companies: Pardes Biosciences Inc (Director · Dec 23, 2021 – Aug 31, 2023 · Past) | Chief Medical Officer · Jul 10, 2014 – Mar 29, 2019 · Past |
| Anuj Gaggar | Chief Medical Officer · Since at least Nov 8, 2023 |
| Jacqueline Sybil Papkoff | SVP-CSO Microbiome · Apr 2, 2018 – Dec 14, 2020 · Past |
| Jason Okazaki | Chief Executive Officer & President, Director · Since at least Mar 26, 2020 |
| Jeanette M Bjorkquist | PFO and PAO · Since at least Sep 9, 2022 |
| Joseph Felder | Director · Dec 15, 2010 – Mar 6, 2013 · Past |
| Lisa Johnson-Pratt | Director · Since at least May 20, 2021 |
| Luisa M Stamm | Chief Medical Officer · Nov 6, 2019 – Mar 29, 2022 · Past |
| Michael Houghton | Director · Since at least Jul 19, 2021 |
| Nicole S White | Chief Manufacturing Officer · Since at least Sep 13, 2023 |
| Richard James Colonno | EVP & CSO, Virology Ops · Mar 29, 2017 – Mar 27, 2020 · Past |
| Rob Cook | Director · Since at least Nov 4, 2026 |
| Robert Donald Cook II | Director · Mar 13, 2024 – Mar 13, 2024 · Past |
| Shannon Ryan | SVP, Investor Relations, Corporate Affairs and Alliance Management · Since at least Nov 7, 2025 |
| Thomas E Rollins | Chief Development Officer · Feb 17, 2016 – Mar 29, 2018 · Past |
| Tomas Cihlar | Director · Since at least Dec 7, 2023 |
| William E Delaney IV | Chief Scientific Officer · Since at least May 27, 2020 |
Log in to ask 6ix AI your own questions about Assembly Biosciences, Inc.